Is Tesamorelin Legal in Europe?
Is Tesamorelin legal in Europe? It was never authorised by the EMA — an application was withdrawn in 2012 — so in the EU it is a research reagent only. An honest, source-cited look at what 'legal' really means, including its WADA status.
Tesamorelin has never been authorised as a medicine in the European Union. A marketing-authorisation application was submitted in 2011 and withdrawn by the applicant in 2012 before the EU regulator finished its review, so no EU physician can lawfully prescribe it. It is FDA-approved in the United States (as Egrifta) but that approval has no standing in the EU. In Europe it is supplied legitimately only as a research-use-only reference material, never for human use. The honest question is not 'is Tesamorelin legal' but 'legal for what': handling it as a characterised research reagent is lawful in much of the EU; using or supplying it for human consumption is not — and it is explicitly named on the WADA Prohibited List.
Tesamorelin occupies one of the more confusing positions a peptide can hold in Europe: a fully approved prescription medicine on one side of the Atlantic, a laboratory reagent with no medicinal standing on the other — and the story most often told about its European status is simply false. The compound was never “approved then withdrawn” in the EU. That gap between rumour and record is exactly where the question “is Tesamorelin legal in Europe” goes wrong, because legality was never a property of the molecule. It is a property of what you intend to do with it, and in which jurisdiction.
Was Tesamorelin ever approved as a medicine in Europe?
No. Tesamorelin holds no marketing authorisation from the European Medicines Agency (EMA), and it carries no authorisation in any individual EU member state.1 A marketing-authorisation application was in fact submitted in 2011 by Ferrer Internacional, S.A., for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy — but the company withdrew that application in 2012, before the EU regulator’s Committee for Medicinal Products for Human Use (CHMP) had completed its evaluation.12 Because no authorisation was ever granted, there is no lawful route by which an EU physician can prescribe Tesamorelin as a medicine. This is the decisive fact, and it does most of the work in any honest answer: Tesamorelin is not a licensed European drug that happens to be hard to find — it is a compound that has never cleared the EU regulatory gate.
That is true even though Tesamorelin has a substantial research record. The molecule is a synthetic 44-amino-acid analogue of growth-hormone-releasing hormone (GHRH), studied for its capacity to stimulate the pituitary gland’s release of growth hormone.3 A documented research history, and even an approval elsewhere, is not the same as a European authorisation; one is evidence generated in a lab or clinic, the other is a legal status conferred by a regulator after formal review.
The myth to correct: “approved then withdrawn” in the EU
This is the single most repeated error about Tesamorelin, and it is worth stating plainly: Tesamorelin was never approved and then withdrawn in the European Union. What happened is narrower. The applicant submitted a marketing-authorisation application and then withdrew it in 2012 while the CHMP’s review was still ongoing — at the time of withdrawal the Committee still had open concerns, including that the reduction in abdominal fat had not been shown to be clinically meaningful as a health benefit, that elevated insulin-like growth factor 1 (IGF-1) raised concerns about cancer risk and worsening of diabetic eye disease, and that the study population was not representative of European patients.12 A withdrawn application is not a withdrawn authorisation: there was never an EU marketing authorisation in existence to lose. Sources that call Tesamorelin a once-approved European medicine are conflating the application stage with an approval that never came.
| Question | Status under the verified facts |
|---|---|
| Approved as a medicine in the EU (EMA or member state) | No — never authorised |
| “Approved then withdrawn” in the EU | No — withdrawn at the application stage (2012), never approved |
| Approved as a medicine outside the EU | Yes — FDA-approved in the US as Egrifta |
| US approval valid inside the EU | No — does not transfer to the Union |
| Prescribable by an EU physician | No — no lawful route exists |
| Sold as a research chemical (RUO reference material) | Yes — in much of the EU |
| Supply for human use in the EU | Not permitted |
| Scheduled narcotic | No |
| Named on the WADA Prohibited List | Yes — explicitly (S2.2.4, GHRH analogues; prohibited at all times) |
Tesamorelin at a glance: an approval abroad and a research-reagent status at home are both true, the EU application was withdrawn before any approval, and neither makes it a European medicine.
So how is Tesamorelin “approved” at all?
Because it is approved somewhere else. Tesamorelin is approved by the United States Food and Drug Administration as Egrifta — first cleared in 2010, with later formulations marketed as Egrifta SV and Egrifta WR — for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy, on a prescription-only basis.4 That US status is genuine, but it is also a source of confusion, because an authorisation granted outside the EU does not transfer into it. EU medicines law is built on Directive 2001/83/EC, the Community code relating to medicinal products for human use,5 and a non-EU approval has no legal standing under that framework. The honest summary is blunt: Tesamorelin being a prescription medicine in the United States tells you nothing about whether you can lawfully use it as a medicine in Madrid, Berlin or Prague. You cannot.
Why is Tesamorelin sold across Europe, then?
Because there are two distinct markets, and only one of them is legitimate. Tesamorelin is supplied in much of the EU strictly as a research chemical — a characterised reference material offered on a “for research use only” basis.16 Handling it that way is lawful in many member states. What is not permitted is selling, labelling or supplying Tesamorelin for human use. The moment a product is offered or described for human consumption, it leaves research-reagent territory and enters the regulated medicines regime — and a medicine can be a medicine “by presentation” or “by function,” so the framing does not depend on a marketing claim alone.5 This boundary deserves extra honesty for Tesamorelin: because the compound already carries a human-use indication abroad, the research-reagent framing is harder to hold than for a molecule with no approval anywhere, which is precisely why the for-human-use line must be drawn firmly rather than blurred.
Tesamorelin is legal to handle as a research reference material in much of the EU, has no lawful route to use as a medicine anywhere in the Union, and is explicitly named on the WADA Prohibited List as banned in sport at all times. All three statements are true at the same time.
Zero EU member states have authorised Tesamorelin as a medicine; the only EU application was withdrawn in 2012 before any approval was reached.
Does the law say the same thing in every EU country?
No, and this is where confident blanket claims fail. Each member state applies its own national medicines law, transposed from the shared EU framework of Directive 2001/83/EC.5 A directive is not a single rulebook applied identically across the bloc; it is a common architecture that each country writes into its own national law, so the classification, handling and enforcement around an unapproved compound can differ from one member state to the next even though the underlying European framework is the same.5 Tesamorelin is not a scheduled narcotic, psychotropic or anabolic substance in this picture — but that is not a clean bill of legal health. Possession, importation or use for human purposes can attract penalties in some jurisdictions even where the same compound circulates freely as a research reagent elsewhere.
Is Tesamorelin banned in sport?
Here, unlike many research peptides, the answer is unambiguous. Tesamorelin is explicitly named on the World Anti-Doping Agency’s Prohibited List, under class S2.2.4 — growth-hormone-releasing factors, which covers GHRH and its analogues — and it is prohibited at all times, both in and out of competition.7 It is classified as a non-specified substance. There is no grey zone or catch-all ambiguity to parse here: any athlete subject to anti-doping rules should treat Tesamorelin as a banned substance, full stop. For the wider context of which peptides anti-doping authorities target and why, see peptides banned by WADA in 2026. We flag this not as a feature of the compound but as a reason for caution — a named entry on the Prohibited List is one of the clearest signals that a substance sits well outside any casual “is it allowed” calculus.
What should an honest answer concede?
Plenty. The US approval is real, and it genuinely does not help you in the EU. The “approved then withdrawn in Europe” story is not a harmless simplification — it is false, and it matters, because it implies a European medicinal pedigree the compound never had. The country-by-country variation is real, not a rhetorical hedge: an arrangement that is unremarkable in one member state may attract penalties in another once human use enters the frame.5 The doping position, by contrast, is not unsettled at all — it is explicitly prohibited.7 And the central caveat bears repeating: none of the above is a route to using Tesamorelin in or on a human being. The legality that exists is that of a research reagent, and it evaporates the instant the use case changes. For how Condor Research draws these lines across its catalogue, see our regulatory position.
Everything Condor Research supplies in this category is a characterised research reference material, sold strictly for research use only.16 It is not an approved or prescribable EU medicine, it is not intended for human or veterinary use, and nothing here is a recommendation to use any compound. This article is for informational purposes only and is not legal advice; responsibility for knowing and complying with applicable local regulation rests with the purchaser. The distinction between a regulated, approved medicine and an RUO reference material is not a formality — it is the entire legal and scientific basis on which legitimate supply rests.
Research Use Only. This material is supplied strictly as a characterised reference reagent for in-vitro and laboratory research. It is not an approved medicine, is not for human or veterinary use, and nothing above is medical or legal advice. — Condor Research · Scientific desk
- Tesamorelin has never held an EU marketing authorisation; an application submitted in 2011 was withdrawn by the company in 2012 before the EU regulator completed its evaluation, so no EU physician can lawfully prescribe it.
- A widely repeated claim that Tesamorelin was "approved then withdrawn" in the EU is wrong: the withdrawal happened at the application stage — it never held a European marketing authorisation in the first place.
- It is FDA-approved in the United States as Egrifta (prescription-only, for HIV-associated lipodystrophy), but an approval outside the EU does not transfer into it under the EU medicines framework (Directive 2001/83/EC).
- In the EU, Tesamorelin is supplied legitimately only as a research chemical (research use only); offering, labelling or supplying it for human use is not permitted, and that framing is harder to hold for a compound with an existing human-use indication abroad.
- Tesamorelin is not a scheduled narcotic, but it is explicitly named on the WADA 2026 Prohibited List (class S2.2.4, GHRH analogues) and is prohibited in sport at all times — a clear reason for caution rather than a clean "allowed".
Was Tesamorelin ever approved as a medicine in the EU?
No. A marketing-authorisation application was submitted in 2011 and withdrawn by the applicant in 2012, before the EU regulator completed its evaluation. Tesamorelin has never held an EU marketing authorisation, so no EU physician can lawfully prescribe it. It is supplied legitimately in Europe only as a research-use-only reference material.
Wasn't Tesamorelin "approved and then withdrawn" in Europe?
No — this is the most common error about its status. The withdrawal occurred at the application stage in 2012, before any approval was granted. A withdrawn application is not the same as a withdrawn authorisation: Tesamorelin never held an EU marketing authorisation that could be withdrawn.
It is FDA-approved in the United States — doesn't that count in Europe?
No. Tesamorelin is approved by the FDA as Egrifta for HIV-associated lipodystrophy, but a US approval has no legal standing inside the EU. EU medicines are governed by Directive 2001/83/EC, transposed into each member state's national law; the US indication creates no lawful route to prescribe or supply Tesamorelin as a medicine in the Union.
If it is sold in Europe, doesn't that mean it is legal to use?
Not for human use. Tesamorelin is supplied in much of the EU strictly as a research chemical. Selling, labelling or supplying it for human consumption is not permitted; the legality attaches to handling it as a reference material, not to using it on a person.
Is Tesamorelin banned in sport under WADA rules?
Yes. Unlike many research peptides, Tesamorelin is explicitly named on the WADA Prohibited List under class S2.2.4 (growth-hormone-releasing factors / GHRH analogues) and is prohibited at all times, both in and out of competition. Any athlete should treat it as a banned substance.